Replies to post #2492 on Synaptogenix Inc (SNPX)

[InTheTrenches]

Before today's mailbag, AdamF had the following comment about NTRP on March 21st:

An earlier study conducted in 2015 tested a single dose of bryostatin in six Alzheimer's patients. The drug was found to be safe but there was no change in cognition in the bryostatin-treated patients compared to placebo-treated patients, according to Neurotrope. A handful of Alzheimer's patients have also been treated with bryostatin under compassionate use regulations.

This is the extent of Adam's due diligence, a quick peek at the phase 2a data, and not even commenting on the dramatic improvements of the compassionate-use patients. Exactly as kid2 states. AdamF works for "TheStreet.com", but this also appears to be the opinion of "The Street".

It will take good Phase 2b data to convince AdamF and "The Street". I'm looking forward to this data. Hopefully dramatic enough to convince "TheStreet.com" and "The Street".